Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD

2  -0.33 (-14.16%)

After market: 2.04 +0.04 (+2%)

Fundamental Rating

3

Taking everything into account, CLLS scores 3 out of 10 in our fundamental rating. CLLS was compared to 556 industry peers in the Biotechnology industry. CLLS may be in some trouble as it scores bad on both profitability and health. CLLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CLLS had negative earnings in the past year.
CLLS had a positive operating cash flow in the past year.
CLLS had negative earnings in each of the past 5 years.
In the past 5 years CLLS reported 4 times negative operating cash flow.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

CLLS has a better Return On Assets (-14.12%) than 81.65% of its industry peers.
CLLS has a better Return On Equity (-41.34%) than 69.96% of its industry peers.
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLLS has a better Gross Margin (4.64%) than 72.48% of its industry peers.
CLLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLLS has more shares outstanding
Compared to 5 years ago, CLLS has more shares outstanding
CLLS has a better debt/assets ratio than last year.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.87, we must say that CLLS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CLLS (-0.87) is comparable to the rest of the industry.
The Debt to FCF ratio of CLLS is 4.88, which is a neutral value as it means it would take CLLS, 4.88 years of fcf income to pay off all of its debts.
CLLS has a Debt to FCF ratio of 4.88. This is amongst the best in the industry. CLLS outperforms 92.99% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that CLLS is somewhat dependend on debt financing.
CLLS's Debt to Equity ratio of 0.65 is on the low side compared to the rest of the industry. CLLS is outperformed by 74.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Altman-Z -0.87
ROIC/WACCN/A
WACC6.27%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

CLLS has a Current Ratio of 1.73. This is a normal value and indicates that CLLS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.73, CLLS is doing worse than 79.14% of the companies in the same industry.
A Quick Ratio of 1.73 indicates that CLLS should not have too much problems paying its short term obligations.
The Quick ratio of CLLS (1.73) is worse than 78.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.54% over the past year.
Looking at the last year, CLLS shows a very strong growth in Revenue. The Revenue has grown by 357.43%.
CLLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.44% yearly.
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
Revenue 1Y (TTM)357.43%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.12%

3.2 Future

Based on estimates for the next years, CLLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -75.28% on average per year.
Based on estimates for the next years, CLLS will show a very strong growth in Revenue. The Revenue will grow by 30.02% on average per year.
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue Next Year63.01%
Revenue Next 2Y30.93%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

CLLS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CLLS is cheaper than 96.58% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.48
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

CLLS's earnings are expected to decrease with -75.28% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%

More info and screens

0

5. Dividend

5.1 Amount

CLLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS - ADR

NASDAQ:CLLS (7/24/2025, 5:20:00 PM)

After market: 2.04 +0.04 (+2%)

2

-0.33 (-14.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)07-31 2025-07-31
Inst Owners18.59%
Inst Owner Change0%
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap200.65M
Analysts84.62
Price Target7.87 (293.5%)
Short Float %0.39%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82%
Min EPS beat(2)18.3%
Max EPS beat(2)145.69%
EPS beat(4)4
Avg EPS beat(4)73.41%
Min EPS beat(4)6.42%
Max EPS beat(4)145.69%
EPS beat(8)6
Avg EPS beat(8)27.22%
EPS beat(12)9
Avg EPS beat(12)23.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)108.7%
Min Revenue beat(2)55.84%
Max Revenue beat(2)161.56%
Revenue beat(4)4
Avg Revenue beat(4)91.56%
Min Revenue beat(4)50.31%
Max Revenue beat(4)161.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.27%
PT rev (3m)40.35%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.13%
EPS NY rev (1m)0.03%
EPS NY rev (3m)0.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)46.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.72
P/FCF 10.48
P/OCF 8.73
P/B 1.53
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)0.19
FCFY9.54%
OCF(TTM)0.23
OCFY11.46%
SpS0.74
BVpS1.31
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.64%
FCFM 25.96%
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Debt/EBITDA N/A
Cap/Depr 19.36%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -0.87
F-Score7
WACC6.27%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue 1Y (TTM)357.43%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.12%
Revenue Next Year63.01%
Revenue Next 2Y30.93%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%
EBIT growth 1Y35.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.14%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y174.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y192.9%
OCF growth 3YN/A
OCF growth 5YN/A